INITIAL GOALS

Operationalize GBM AGILE into a self-sustaining
engine of therapeutic and biomarker development
for patients with GBM.
Finance the launch and ongoing activity of new
GBM-focused therapies developed through
GBM AGILE.
Use GBM AGILE as a model for developing an efficient
framework for the discovery and development of
therapies and biomarkers for other rare and deadly diseases.
Randall Garnick Photography, National Brain Tumor Society

LEADERSHIP

The Global Coalition for Adaptive Research (GCAR) is an international partnership

The Global Coalition for Adaptive Research (GCAR) is an international partnership comprised of some of the world’s foremost clinical, translational, and basic science investigators. Through this collaboration and open exchange of ideas, the ultimate beneficiary—the patient—is supported in the fight against rare and deadly diseases.

READ MORE

GBM AGILE is a seamless Phase II (Efficacy and Safety) / Phase III (Confirmatory) trial to identify effective therapies and the most promising biomarker-defined populations for those therapies in patients with glioblastoma.

GBM AGILE is changing the IDEA of clinical trials

Innovative – Next-generation trial that will lower cost of development and speed progress.

Dynamic – Perpetual learning system to quickly add potentially promising new drugs and drop those that appear to be ineffective.

Efficient – Design and trial structure that will require fewer patients and a shorter time frame to get important answers about a drug's effectiveness.

Accessible – Global effort open to a broad patient population of newly diagnosed and recurrent GBM patients.
LEARN MORE

NEWS

REMAP-CAP to Partner With Eisai on Innovative Trial to Combat COVID
JUNE 30, 2020  |  BUSINESSWIRE
DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research
JUNE 24, 2020  |  PRNEWSWIRE
Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals’ VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme
JUNE 4, 2020  |  PRNEWSWIRE
Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial
MAY 14, 2020  |  ONCLIVE
International trial uses AI to rapidly identify optimal Covid-19 treatments
APRIL 9, 2020  |  STAT
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
December 11, 2019  |  PRNEWSWIRE
Henry Ford Cancer Institute Enrolls First Patient in World’s Largest Brain Cancer Clinical Trial
AUGUST 14, 2019  |  BIO SPACE
Global Coalition for Adaptive Research’s Innovative Clinical Trial Platform Opens to Evaluate New Therapies for Brain Cancer
JUNE 19, 2019  |  BUSINESS WIRE
Global Coalition for Adaptive Research (GCAR) Appoints Jeffrey Tarrant to Board of Directors
JUNE 13, 2019  |  BUSINESS WIRE
FDA’s Woodcock Defends Accelerated Approvals and Talks of Culture Shift in Clinical Trials
JUNE 5, 2019  |  BIOPHARMA DIVE
ALL NEWS

GET INVOLVED

CONTACT US

For additional information about GCAR and to learn how you can collaborate with us, please contact:
GENERAL INQUIRIES
MEDIA INQUIRIES